https://chksignals.com/index.p....hp/international-dev
We retrospectively examined the medical functions and survival outcomes in 474 successive patients with MM receiving immunomodulatory drugs or proteasome inhibitor-based regimens as first-line treatments. 1q21 + had been detected in 249 (52.5%) customers. Patients with 1q21 + had a greater percentage of subtypes of IgA, IgD, and λ-light sequence than non-1q21 + . 1q21 + was associated with more advanced ISS stage and ended up being more frequently combined with del(13q), elevated lactate d
Like
Comment
Share
